A5005215114- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Pulmonary Hypertension Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Valve Diseases and Treatments
- Cardiovascular Disease and Adiposity
- Atrial Fibrillation Management and Outcomes
- Cardiovascular and exercise physiology
- Blood Pressure and Hypertension Studies
- Hormonal Regulation and Hypertension
- Parathyroid Disorders and Treatments
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Systemic Sclerosis and Related Diseases
- Pancreatic function and diabetes
- Cardiovascular Health and Disease Prevention
- Cardiovascular Health and Risk Factors
- HIV-related health complications and treatments
- Potassium and Related Disorders
- Cardiomyopathy and Myosin Studies
- Peptidase Inhibition and Analysis
- Metabolism, Diabetes, and Cancer
Northwestern University
2016-2025
Max Super Speciality Hospital
2025
Cardiovascular Institute of the South
2010-2024
National Heart Centre Singapore
2024
British Heart Foundation
2024
National Heart Hospital
2024
University of Missouri–Kansas City
2023-2024
Brigham and Women's Hospital
2013-2024
Harvard University
2012-2024
Georgetown University
2023-2024
Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated effects of spironolactone in preserved fraction.In this randomized, double-blind trial, we assigned 3445 symptomatic fraction 45% or more to receive either (15 45 mg daily) placebo. The primary outcome was composite death from cardiovascular causes, aborted cardiac arrest, hospitalization management failure.With mean follow-up 3.3 years,...
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin fibrils in myocardium. The occurs when wild-type or variant becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation amyloidogenesis.In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 441 patients with 2:1:2 ratio receive 80 mg tafamidis, 20 placebo for 30 months. In primary analysis, hierarchically assessed all-cause...
The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with and ejection fraction. effect inhibition in preserved fraction is unclear.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic a left ventricular ejection fraction 40% or less. Whether SGLT2 are effective in higher remains less certain.
Background— Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome in need of improved phenotypic classification. We sought to evaluate whether unbiased clustering analysis using dense data (phenomapping) could identify phenotypically distinct HFpEF categories. Methods and Results— prospectively studied 397 patients performed detailed clinical, laboratory, ECG, echocardiographic phenotyping the study participants. used several statistical learning...
Background— Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection fraction assigned to spironolactone did not achieve a significant reduction in the primary composite outcome (time cardiovascular death, aborted cardiac arrest, or hospitalization for management failure) compared receiving placebo. In post hoc analysis, ≈4-fold difference was identified this event rate between 1678...
Automated cardiac image interpretation has the potential to transform clinical practice in multiple ways, including enabling serial assessment of function by nonexperts primary care and rural settings. We hypothesized that advances computer vision could enable building a fully automated, scalable analysis pipeline for echocardiogram interpretation, (1) view identification, (2) segmentation, (3) quantification structure function, (4) disease detection.Using 14 035 echocardiograms spanning...
BackgroundHeart failure with preserved ejection fraction is increasing in prevalence and associated a high symptom burden functional impairment, especially persons obesity. No therapies have been approved to target obesity-related heart fraction.MethodsWe randomly assigned 529 patients who had body-mass index (the weight kilograms divided by the square of height meters) 30 or higher receive once-weekly semaglutide (2.4 mg) placebo for 52 weeks. The dual primary end points were change from...
Abstract Aims To date, clinical evidence of microvascular dysfunction in patients with heart failure (HF) preserved ejection fraction (HFpEF) has been limited. We aimed to investigate the prevalence coronary (CMD) and its association systemic endothelial dysfunction, HF severity, myocardial a well defined, multi-centre HFpEF population. Methods results This prospective multinational observational study enrolled fulfilling strict criteria for according current guidelines. Those known...
Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily such patients.In this multicenter, double-blind, crossover study, 110 fraction were randomly assigned 6-week dose-escalation regimen (from 30 mg 60 120 once daily) placebo, subsequent other group for 6 weeks. The primary end point was level, quantified as average accelerometer units during 120-mg...
The aim of the present study was to determine contemporary survival in pulmonary arterial hypertension (PAH), and investigate whether or not National Institutes Health (NIH) equation remains an accurate predictor survival. In 576 patients with PAH referred during 1991–2007, observed described using Kaplan–Meier method. idiopathic, familial anorexigen-associated (n = 247), versus NIH predicted compared. A new prediction developed exponential regression analysis. 1-, 3- 5-yr total cohort were...
While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in preserved (HFpEF) TOPCAT trial, which enrolled LVEF 45% greater. We utilized data from assess relationship between as well outcomes and efficacy spironolactone. assessed differences baseline characteristics across...
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms functional limitations, poor quality life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial patients HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves primary endpoint Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS),...
The aim of this study was to define the epidemiology World Health Organization (WHO) Group I pulmonary arterial hypertension (PAH) in a large referral centre USA. Pulmonary Hypertension Connection registry, initiated 2004, evaluated all patients single USA practice from 1982–2006. For comparison, authors divided group by incident versus prevalent cohorts, aetiology and treatment era. In total, 578 (77% female) aged 48±14 yrs were entered. Of these, 80% had class III or IV symptoms. Over...
Impairment in left ventricular systolic function has been described heart failure (HF) with preserved ejection fraction (HFpEF), but its prognostic relevance is not known. We determined whether longitudinal strain (LS) predictive of cardiovascular outcomes HFpEF beyond clinical and conventional echocardiographic measures.
Background— Heart failure with preserved ejection fraction (HFpEF) is associated substantial morbidity and mortality. Existing data on cardiac structure function in HFpEF suggest significant heterogeneity this population. Methods Results— Echocardiograms were obtained from 935 patients (left ventricular ≥45%) enrolled the Treatment of Preserved Cardiac Function Failure an Aldosterone Antagonist (TOPCAT) trial before initiation randomized therapy. Average age was 70±10 years, 49% women, 14%...